АТИПИЧНЫЙ ГЕМОЛИТИКО-УРЕМИЧЕСКИЙ СИНДРОМ
https://doi.org/10.24884/1561-6274-2012-16-2-16-48
Аннотация
Гемолитико-уремический синдром (ГУС) характеризуется триадой, представленной механической гемолитической анемией, тромбоцитопенией и почечной недостаточностью. Атипичным ГУС (аГУС) считается ГУС, не связанный с действием Шига-токсина, и хотя ряд авторов выделяют вторичный аГУС, обусловленный S. pneumoniae или другими причинами, аГУС представляет собой первичное заболевание, обусловленное нарушением регуляции альтернативного пути активации комплемента. Среди случаев ГУС у детей только 5–10% можно отнести к атипичным, тогда как у взрослых атипичными являются подавляющее число случаев ГУС. Частота встречаемости комплемент-зависимого аГУС на сегодняшний день точно неизвестна. Тем не менее, сообщается более чем о 1000 пациентах с аГУС, обследованных на наличие нарушений системы комплемента. Развитие заболевания возможно от неонатального периода и до взрослого возраста. У большинства пациентов аГУС манифестирует гемолитической анемией, тромбоцитопенией и почечной недостаточностью, и у 20% отмечаются внепочечные проявления. От 2 до 10% больных умирают, у одной трети пациентов развивается терминальная почечная недостаточность при первой атаке. У половины пациентов отмечаются рецидивы заболевания. Обнаружено наличие мутаций генов, кодирующих регуляторные белки системы комплемента, фактора Н, мембранного кофакторного белка (MCP), фактора I и тромбомодулина, у 20–30, 5–15, 4–10 и 3–5% соответственно и мутации генов кодирующих белки С3-конвертазы, С3 и фактора В – у 2–10% и 1–4%. Кроме того, у 6–10% пациентов выявляются антитела к фактору Н. Критериями постановки диагноза аГУС являются: 1) отсутствие ассоциированного заболевания; 2) отсутствие критериев ГУС, связанного с Шига-токсином (посев кала и ПЦР на Шига-токсины; серология на антилипополисахаридные антитела); 3) отсутствие критериев тромботической тромбоцитопенической пурпуры (активность ADAMTS13 сыворотки больше 10%). Необходимо исследование системы комплемента (С3,С4, концентрации в плазме фактора Н и фактора I, экспрессии на лейкоцитах MCP и антител к фактору Н; генетический скрининг факторов риска). При анализе родословных, по крайней мере, у 20% заболевание имело наследственный характер с аутосомно-рецессивным или доминатным путем наследования. В связи с тем, что пенетрантность заболевания составляет 50%, генетическое консультирование крайне затруднено. До настоящего времени терапией первой линии является плазмотерапия, при отсутствии бесспорных доказательств её эффективности. При трансплантации, за исключением случаев MCP-ГУС, существует высокий риск посттрансплантационных рецидивов. Описанные клинические случаи и два исследования второй фазы демонстрируют впечатляющую эффективность блокатора C5 компонента комплимента экулизумаба, предполагая, что он будет являться следующим стандартом терапии. За исключением пациентов, получающих интенсивную плазмотерапию или терапию экулизумабом, наихудший прогноз отмечается у пациентов с H-фактором – ГУС, при котором смертность может достигать 20%, а у 50% выживших пациентов функция почек не восстанавливается. Терминальная почечная недостаточность развивается у половины больных с I-фактором ГУС. У большинства пациентов с MCP-ГУС функция почек, напротив, остается сохранной. У пациентов с ГУС, обусловленным действием антител к фактору Н (анти-Н-ГУС) при раннем начале терапии отмечается благоприятный исход.
Вклад авторов. CL и VFB обсудили содержание статьи, написали оригинал, редактировали его и утвердили окончательный вариант. VFB выполнил исследование системы комплемента и генетический скрининг.
Конфликт интересов. С. Loirat была координатором французского исследования «Безопасность и эффективность экулизумаба у взрослых пациентов с аГУС, резистентных/чувствительных к плазмотерапии «C08-002A и C08-003A», является координатором французских исследований «Применение экулизумаба у взрослых и детей с аГУС «С10-004 и С10-003», а также является членом научноконсультативного совета при Alexion Pharmaceutical sand LFB Biotechnologies. В. Frémeaux-Bacchi является членом научно-консультативного совета при Alexion Pharmaceuticals.
Ключевые слова
Об авторах
Ш. ЛораФранция
отделение детской нефрологии
Chantal Loirat. Pediatric Nephrology Department; Paris
В. Фремю-Бачи
Франция
отделение биологической иммунологии
Е. В. Воронкова
Россия
Перевод с английского
Список литературы
1. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006;70:423–431
2. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:1035–1050. doi: 10.1681/ASN.2004100861
3. Johnson S, Taylor CM. What’s new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965–971
4. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today’s understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010;169:7–13
5. Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol 2011;26:523–533
6. Allen U, Licht C. Pandemic H1N1 influenza A infection and (atypical) HUS-more than just another trigger? Pediatr Nephrol 2011;26:3–5
7. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, Birembaut P, Chanard J, Rieu P. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. J Transplan 2005;5:2441–2447
8. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010;115:1098–1105
9. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;5:203–218
10. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129–1136
11. Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noël LH, Knebelmann B. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009;24:682–685
12. Sharma AP, Greenberg CR, Prasad AN, Prasad C. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol 200;22:2097–2103
13. Van Hove JL, Van Damme-Lombaerts R, Grünewald S, Peters H, Van Damme B, Fryns JP, Arnout J, Wevers R, Baumgartner ER, Fowler B. Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet 2002;111:195–201
14. Adams D, Venditti CP. In: Disorders of Intracellular Cobalamin Metabolism. Pagon RA, Bird TC, Dolan CR, Stephens K, editor. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle 1993; 2008 [updated 2009 Aug 11]
15. Kaplan BS, Chesney RW, Drummond KN. Hemolytic uremic syndrome in families. N Engl J Med 1975;292:1090–1093
16. Fakhouri F, Fremeaux-Bacchi V. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007;3:679–687
17. Sellier-Leclerc AL, Fremeaux-Bacchi V, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fishbach M, Morin D, Nivet H, Alberti C, Loirat C. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007;18:2392–2400
18. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844–1859
19. Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, Trachtman H. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;43:976–982
20. Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome Ann Hum Genet 2010;74:17–26
21. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelleti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267–1279
22. Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, van Kaauwen E, van der Velden T, van de Kar N, van den Heuvel L. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS) Nephrol Dial Transplant 2010;25:2195–2202
23. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010;31:E1445–1460
24. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A. French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010;5:e10208
25. Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500–1511
26. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005;14:703–712
27. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, Fridman WH, Frémeaux-Bacchi V. The high frequency of Complement Factor H-Related CFHR1 Gene deletion is restricted to specific subgroups of patients with atypical Haemolytic Uraemic Syndrome. J Med Genet 2009;46:447–450
28. Bienaimé F, Dragon-Durey M-A, Regnier CH, Nillson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti M-A, Loirat C, Sautés-Fridman C, Villoutreix BO, Blom AM, FremeauxBacchi V. Mutations in components of complement influences the outcome of Factor Iassociated atypical hemolytic uremic syndrome. Kidney Int 2009;77:339–349
29. Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child 1990;65:716–721
30. Surveillance of post-diarrheal hemolytic uremic syndrome in children less than 15 years of age in France. Institut de Veille Sanitaire, Ministère de la Santé, France; http://www.invs.sante.fr
31. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome. Pediatr Nephrol 2008;23:1957–1972
32. Kwon T, Belot A, Ranchin B, Baudouin V, FremeauxBacchi V, Dragon-Durey MA, Cochat P, Loirat C. Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases. Nephrol Dial Transplant 2009;24:2752–2754
33. Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, Strain L, Goodship TH, Meneses-Oliveira C. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1) Ren Fail 2010;32:753–756
34. Trachtman H, Sethna C, Epstein R, D'Souza M, Rubin LG, Ginocchio CC. Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection. Pediatr Nephrol 2011;26:145–146
35. Caltik A, Akyüz SG, Erdogan O, Demircin G. Hemolytic uremic syndrome triggered with a new pandemic virus: influenza A (H1N1) Pediatr Nephrol 2011;26:147–148
36. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis and the HELLP syndrome. Blood 2007;111:624–632
37. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong H, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V. Clinical features of anti-factor h autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010;21:2180–2187
38. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676–1687
39. Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F, Rondeau E, Frémeaux-Bacchi V. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859-867
40. Koehl B, Boyer O, Biebuyck-Gougé N, Kossorotoff M, Frémeaux-Bacchi V, Boddaert N, Niaudet P. Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2010;25:2539–2542
41. Sallée M, Daniel L, Piercecchi MD, Jaubert D, FremeauxBacchi V, Berland Y, Burtey S. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant 2010;25:2028–2032
42. Kaplan BS, Garcia CD, Chesney RW, Segar WE, Giugno K, Chem R. Peripheral gangrene complicating idiopathic and recessive hemolytic uremic syndromes. Pediatr Nephrol 2000;14:985–989
43. Cameron JS, Vick R. Letter: Plasma-C3 in haemolyticuraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 1973;2:975
44. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058–1066
45. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical Hemolytic-Uremic Syndrome. N Engl J Med 2009;361:345–357
46. Rodrigues de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008;151:1–13
47. Kajander T, Lehtinen MJ, Hyvärinen S, Bhattacharjee A, Leung E, Isenman DE, Meri S, Goldman A, Jokiranta TS. Dual interaction of factor H with C3d and glycosaminoglycans in hostnonhost discrimination by complement. Proc Natl Acad Sci USA 2011;108:2897–2902
48. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, Kavanagh D, Mertens HD, Svergun DI, Johansson CM, Uhrín D, Barlow PN, Hannan JP. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 2011;18:463–470
49. Kavanagh D, Richards A, Atkinson J. Complement regu latory genes and haemolytic uremic syndromes. Annu Rev Med 2008;59:293–309
50. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431–2442
51. Sánchez-Corral P, Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010;150:529–542
52. Stahl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008;111:5307–5315
53. Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH. Platelet-associated complement factor H in normal individuals and patients with atypical HUS. Blood 2009;114:4538–4545
54. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007;204:1249–1256
55. Goicoechea de Jorge E, Paixao-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC. The development of atypical haemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011;22:137–145
56. Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981;46:110–119
57. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA. Genetic studies into inherited and sporadic haemolytic uremic syndrome. Kidney Int 1998;53:836–844
58. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, López Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodríguez de Córdoba S, Sánchez-Corral P, Skerka C, Zipfel PF, Perkins SJ. et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 2007;28:222–234
59. Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, Uhrin D, Barlow PN, Pangburn MK, Kavanagh D. The binding of factor H to a complex physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009;182:7009-7018
60. Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS. Mutations in factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. Biol Chem 2009;284:15650–15658
61. Roumenina LT, Loirat C, Dragon-Durey MA, HalbwachsMecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011;365:8–26
62. Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ, Skerka C, Jokiranta TS, Meyers K, Wagner E, Robitaille P, Esparza-Gordillo J, Rodriguez de Cordoba S, Zipfel PF, Goodship TH. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006;27:292–293
63. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006;3:e431
64. Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003;40:676–681
65. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555–563
66. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007;110:1516–1518
67. Skerka C, Jozsi M, Zipfel PF, Dragon-Durey MA, FremeauxBacchi V. Autoantibodies in haemolytic uraemic syndrome (HUS) Thromb Haemost 2009;101:227–232
68. Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010;25:136–144
69. Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C. Deletion of Complement Factor Hrelated genes CFHR1 and CFHR3 is associated with atypical haemolytic uremic syndrome. PLoS Genetics 2007;3:e41
70. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008;111:1512–1514
71. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010;115:379-387
72. Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-Durey MA, Choi Y, Cheong HI. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009;66:336–340
73. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Müslümanoğlu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003;100:12966–12971
74. Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003;362:1542–1547
75. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, DragonDurey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006;17:2017–2025
76. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004;41:e84
77. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship TH. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:2150–2155
78. Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, Goodship JA, Fremeaux-Bacchi V, Remuzzi G, Goodship TH, Atkinson JP. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95–105
79. Nillson SC, Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead either to altered secretion or altered function of factor I. Eur J Immunol 2010;40:172–185
80. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S. Gain-offunction mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007;104:240–245
81. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009;114:2837– 2845
82. Tawadrous H, Maga T, Sharma J, Kupferman J, Smith RJ, Schoeneman M. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol 2010;25:947–951
83. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, DragonDurey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008;112:4948–4952
84. Lhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, Würzner R, Zimmerhackl LB, Mayer G, Fremeaux-Bacchi V. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 2009;4:1356–1362
85. Esparza-Gordillo J, Jorge EG, Garrido CA, Carreras L, López-Trascasa M, Sánchez-Corral P, de Córdoba SR. Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006;43:1769–1775
86. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, DragonDurey MA, Strain L, Loirat C, Deng HW, Goodship TH. The development of atypical HUS is influenced by susceptibility factors in factor H and membrane cofactor protein-evidence from two independent cohorts. J Med Genet 2005;42:852–856
87. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M. International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003;12:3385–3395
88. Abarrategui-Garrido C, Martínez-Barricarte R, LópezTrascasa M, de Córdoba SR, Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009;114:4261–4271
89. Blom AM, Bergström F, Edey M, Diaz-Torres M, Kavanagh D, Lampe A, Goodship JA, Strain L, Moghal N, McHugh M, Inward C, Tomson C, Frémeaux-Bacchi V, Villoutreix BO, Goodship TH. A novel non-synonymous polymorphism (p.Arg240His) in C4bbinding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008;180:6385–6391
90. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Tylor C, Van De Kar N, Van De Wall J, Zimmerhackl L. Guidelines for the investigation and initial therapy of diarrhea negative haemolytic uraemic syndrome. Pediatr Nephrol 2009;24:687–696
91. Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom. Br J Haematol 2010;148:37–47
92. Huang DT, Chi H, Lee HC, Chiu NC, Huang FY. T-antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia. Pediatr Infect Dis J 2006;25:608–610
93. Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C, Jones C, Pichon B, Reid C, Slack MP, Van’t Hoff W, Dillon MJ, Taylor CM, Tullus K. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151:140–144
94. Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 2008;23:1951–1956
95. Loirat C, Girma JP, Desconclois C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol 2009;24:19–29
96. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G. International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am soc Nephrol 2005;16:1177–1183
97. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93–100
98. Bouts AH, Roofthooft MT, Salomons GS, Davin JC. CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 2010;25:2547–2548
99. Guigonis V, Frémeaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z, Mougenot B, Rosenblatt DS, Deschênes G. Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005;45:588–595
100. Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, Pirson Y, Dürrbach A, Grünfeld JP, Knebelmann B, Frémeaux-Bacchi V. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008;112:4542–4545
101. Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E, Legendre C, Zuber J, Frémeaux-Bacchi V. Complement mutationassociated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008;8:1694–1701
102. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, FremeauxBacchi V, Atkinson JP. Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Med 2011;8:e1001013
103. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:673–681
104. Pichette V, Quérin S, Schürch W, Brun G, Lehner-Netsch G, Delâge JM. Familial hemolyticuremic syndrome and homozygous factor H deficiency 1994;24:936–941
105. Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001;138:412–417
106. Nathanson S, Frémeaux-Bacchi V, Deschênes G. Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 2001;16:554–556
107. Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G. Secondary failure of plasma therapy in factor H deficiency. Pediatr Nephrol 2006;21:1769–1771
108. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005;45:415–421
109. Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiencyassociated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007;22:874–880
110. Stratton JD, Warwicker P. Successful treatment of factor H-related haemolytic uraemic syndrome. Nephrol Dial Transplant 2002;17:684–685
111. Gerber A, Kirchhoff-Moradpour AH, Obieglo S, Brandis M, Kirschfink M, Zipfel PF, Goodship JA, Zimmerhackl LB. Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality. Pediatr Nephrol 2003;18:952–955
112. Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Good ship TH. Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr Nephrol 2004;19:908
113. Davin JC, Strain L, Goodship THJ. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008;23:1517–1521
114. Lapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux-Bacchi V, Goodship TH, Robitaille P. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008;8:1363–1366
115. De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C. Severe atypical HUS caused by CFH S1191L-case presentation and review of treatment options. Pediatr Nephrol 2010;25:97–104
116. Ohali M, Shalev H, Schlesinger M, Katz Y, Kachko L, Carmi R, Sofer S, Landau D. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 1998;12:619–624
117. Abarrategui-Garrido C, Melgosa M, Peña-Carrión A, de Jorge EG, de Córdoba SR, López-Trascasa M, Sánchez-Corral P. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008;52:171–180
118. Sethi SK, Dragon-Durey MA, Thaker N, Hari P, Bagga A. Hemolytic uremic syndrome due to homozygous factor H deficiency. Clin Exp Nephrol 2009;13:526–530
119. Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, Fremeaux-Bacchi V, Trouw LA, Blom AM. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 2007;44:1835–1844
120. Davin JC, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, Goodship T. Prophylactic plasma exchange in CD46- associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009;24:1757–1760
121. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, de Ligny BH. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009;9:2644–2645
122. Kwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A, Peuchmaur M, Fremeaux-Bacchi V, Loirat C. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008;23:2088–2090
123. Lionet A, Provot F, Glowacki F, Veronique FremeauxBacchi V, Hazzan M. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2009;2:458–460
124. Boyer O, Balzamo E, Charbit M, Biebuyck-Gougé N, Salomon R, Dragon-Durey MA, Frémeaux-Bacchi V, Niaudet P. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis 2010;55:923–927
125. Saland JM, Ruggenenti P, Remuzzi G. Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009;20:940–949
126. Michon B, Moghrabi A, Winikoff R, Barrette S, Bernstein ML, Champagne J, David M, Duval M, Hume HA, Robitaille N, Bélisle A, Champagne MA. Complications of apheresis in children. Transfusion 2007;47:1837–1842
127. Witt V, Stegmayr B, Ptak J, Wikström B, Berlin G, Axelsson CG, Griskevicius A, Centoni PE, Liumbruno GM, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Ramlow W, Blaha M, Evergren M, Tomaz J. World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus Apher Sci 2008;39:255–260
128. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship HT, Remuzzi G. Outcome of renal transplantation in patients with Non-Shiga-Toxin associated hemolytic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88–99
129. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transpl 2008;12:619–629
130. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010;10:1517–1523
131. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7:23–35
132. Chan MR, Thomas CP, Torrealba JR, Djamali A, Fernandez LA, Nishimura CJ, Smith RJ, Samaniego MD. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis 2009;53:321–326
133. Le Quintrec M, Zuber J, Noel LH, Thervet E, FrémeauxBacchi V, Niaudet P, Fridman WH, Legendre C, Dragon-Durey MA. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009;9:1223–1229
134. Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, Strain L, Sebire N, Shroff R, Marks SD, Goodship TH, Rees L. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant 2010;10:168–172
135. Oyen O, Strøm EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer P, Brekke IB. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006;6:412–418
136. Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Frémeaux-Bacchi V, Steiger J. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 2009;24:3548–3551
137. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation. Am J Kidney Dis 2010;55:708–711
138. Albertazzi V, Bonucchi D, De Amicis S, Americo C, Ghiandai G, Cappelli G. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report. Transplant Proc 2010;42:1352–1354
139. Cruzado JM, de Córdoba SR, Melilli E, Bestard O, Rama I, Sánchez-Corral P, López-Trascasa M, Navarro I, Torras J, Gomà M, Grinyó JM. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am J Transplant 2009;9:1477–1483
140. Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, Gridelli B. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002;359:1671– 1672
141. Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 2005;5:1146–1150
142. Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, Choi Y. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004;19:454–458
143. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006;6:19481952
144. Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, Pinomäki A, Armstrong E, Koivusalo A, Tukiainen E, Mäkisalo H, Saland J, Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 2008;8:216–221
145. Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:201–206
146. Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ. Successful Isolated Liver Transplantation in a Child with Atypical Hemolytic Uremic Syndrome and a Mutation in Complement Factor H. Am J Transplant 2010;10:2142–2147
147. Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T. Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 2011;58:109–112
148. Salant DJ. Targeting Complement C5 in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2011;22:7–9
149. Brodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev 2008;22:65–74
150. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373:759-767
151. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786–6792
152. Rosales A, Riedl M, Zimmerhackl LB. Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 2010;6:504–506
153. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 2011;26:41–57
154. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010;23:740–780
155. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:544–546
156. Fremont OT, Gordon CA, Hand MM. Eculizumab treatment for aHUS in a child with positive family history. PUB715, 42nd Annual Meeting of the American Society of Nephrology, San Diego, California, USA. 2009
157. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1312–1316
158. Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010;36:669–672
159. Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:621–624
160. Prescott HC, Wu HM, Cataland SR, Baiocchi RA. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol 2010;5:976–977
161. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical haemolytic uremic syndrome. Clin Pharmacology: Advances and Applications 2011;3:5–12
162. Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:542–544
163. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 2010;42:4353–4355
164. Legault DJ, Boelkins MR. Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab. Poster 2421, 51st Meeting of the American Society of Hematology, New Orleans, LA, USA. 2009
165. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010;89:903–904
166. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces longterm remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011;26:613–619
167. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010;362:1746–1748
168. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:1325–1329
169. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P. Pre-emptive Eculizumab and Plasmapheresis for Renal Transplant in Atypical Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol 2011;6:1488–1494
170. Legendre C, Babu S, Furman RR, Sheerin NS, Cohen DJ, Gaber AO, Eitner F, Delmas Y, Loirat c, Greenbaum LA, Zimmerhackl LB. Safety and efficacy of Eculizumab in aHUS resistant to plasma Therapy: interim analysis from a Phase II trial. FC 406, 43rd Annual Meeting of the American Society of Nephrology, Denver, CO, USA. 2010. pp. 16–21
171. Muus P, Legendre C, Douglas K, Hourmant M, Delmas Y, Herthelius BM, Trivelli A, Loirat C, Goodship TH, Licht C. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: Interim analysis of a phase II trial. Poster 1274, 43rd Annual Meeting of the American Society of Nephrology, Denver, CO, USA. 2010. pp. 16–21
172. List of the various Open Label Multicenter Trials of Eculizumab In Atypical Hemolytic Uremic Syndrome. http:// clinicaltrials.gov
173. Emlen W, Li W, Kirschfink M. Therapeutic complement inhibition: new developments. 2010;36:660–668
174. Fakhouri F, de Jorge EG, Brune F, Azam P, Cook HT, Pickering MC. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010;78:279–286
175. Schmidt CQ, Slingsby FC, Richards A, Barlow PN. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif 2011;76:254–263
176. Büttner-Mainik A, Parsons J, Jérôme H, Hartmann A, Lamer S, Schaaf A, Schlosser A, Zipfel PF, Reski R, Decker EL. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol J 2011;9:373–383
177. Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschênes G, Goodship TH, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-Bacchi V. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant 2010;25:3421–3425
178. Davin JC, Majoie C, Groothoff J, Gracchi V, Bouts A, Goodship TH, Loirat C. Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation. Pediatr Nephrol 2011;26:155–157
Рецензия
Для цитирования:
Лора Ш., Фремю-Бачи В., Воронкова Е.В. АТИПИЧНЫЙ ГЕМОЛИТИКО-УРЕМИЧЕСКИЙ СИНДРОМ. Нефрология. 2012;16(2):16-48. https://doi.org/10.24884/1561-6274-2012-16-2-16-48
For citation:
Loirat Ch., Frémeaux-Bacchi V., Voronkova E.V. ATYPICAL HEMOLYTIC UREMIC SYNDROME. Nephrology (Saint-Petersburg). 2012;16(2):16-48. (In Russ.) https://doi.org/10.24884/1561-6274-2012-16-2-16-48